Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples